{"ticker": {"uuid": "b322b82e-6812-408f-9c42-41c81bec7c83", "symbol": "OMER", "name": "Omeros Corporation", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNVGdpcWJ6Vi16ZU5fXzJRNlowRHcyblJ6R0ZKOFhGaEw5RDFVa2tyejExWllpWnZ4MWl5d25uOGlGSEd5WGZXYWhmclJtUmQxMXpURzhrVHg5a0xaV0F1QTduLTRlTWljSUxJLTdkV05SYzE1bWRuWkZibWx6WlRFVjJ2U3IyM181NGJ4czZzSndhYkZCelJHVHBBTQ?oc=5", "source_name": "Market source", "published_at": "2026-07-15T15:43:00+00:00", "published_display": "15 Jul 2026 15:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (OMER)", "summary": "Omeros Corporation (OMER) is experiencing weak near-term sentiment despite long-term strength, with its support levels currently being tested. AI models have generated three trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014tailored to different risk profiles, alon", "url": "https://news.stocktradersdaily.com/news_release/149/Understanding_Momentum_Shifts_in_OMER_071526034002_1784144402.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-15T15:44:09", "published_display": "15 Jul 2026 15:44", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros stock drops 19% after EU rejects key drug application, prompting investor lawsuit.", "summary": "Omeros Corporation's stock dropped 19.12% after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on its drug narsoplimab. This rejection led to Pomerantz LLP launching a securities fraud investigation on behalf of Ome", "url": "https://pluang.com/en/news-feed/peringatan-investor-pomerantz-litigasi-atas-omeros-corporation-omer", "source_name": "Pluang", "published_at": "2026-07-14T22:42:21", "published_display": "14 Jul 2026 22:42", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Corporation Investigated by the Portnoy Law Firm", "summary": "The Portnoy Law Firm has launched an investigation into Omeros Corporation (NASDAQ: OMER) for potential securities fraud and may file a class action lawsuit. This follows a significant 19.12% drop in Omeros's stock price after the European Medicines Agency's committee issued a ne", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326415/0/en/omeros-corporation-investigated-by-the-portnoy-law-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T14:41:02", "published_display": "13 Jul 2026 14:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNRWZyQlAyZjdENUtsVUtLbXpDYml3aFhDZXg4c01hTEdDSjFjLTZ5YUVnU2NvcW9wYmo0cTNSb3NQZUVpOTFYVVFtQVRDS3VKeDRDTzROcTZwQjhDOGk2c2RFWWZEUGl5OUxxeXBJRmFvU1JGRnZDNVFhSzNZM2FMZ0prRFR6MHpobjJyTGJlNlpDOE82dXQxWmhwRy1lX0ZDQlowVE45VlV6aGMyVktXMHlJRVRWMW1DMTM0ZEoySWJoaVNQYkVUYw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-07-08T22:21:00+00:00", "published_display": "08 Jul 2026 22:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm", "summary": "The Schall Law Firm is investigating Omeros Corporation (NASDAQ: OMER) on behalf of investors for potential securities law violations. This follows Omeros's announcement on June 26, 2026, that the European Medicines Agency's CHMP issued a negative opinion on its marketing authori", "url": "https://www.globenewswire.com/news-release/2026/07/08/3324190/0/en/omer-investors-have-opportunity-to-join-omeros-corporation-fraud-investigation-with-the-schall-law-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T19:39:39", "published_display": "08 Jul 2026 19:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros shares drop 19% after EMA rejects narsoplimab drug approval, triggering fraud probe.", "summary": "Shares of Omeros Corporation dropped over 19% after the European Medicines Agency's CHMP issued a negative opinion on its marketing authorization application for narsoplimab, a TA-TMA treatment. This rejection has prompted The Schall Law Firm to launch an investigation into wheth", "url": "https://pluang.com/en/news-feed/investor-omeros-ikut-penyelidikan-kasus-penipuan", "source_name": "Pluang", "published_at": "2026-07-08T17:11:01", "published_display": "08 Jul 2026 17:11", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Corporation (OMER) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Omeros Corporation (NASDAQ:OMER) purchasers following a significant drop in its stock price. This decline occurred after the Committee for Medicinal Products for Human Use (CHMP) of the European Med", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/omeros-corporation-omer-investigation-bronstein-gewirtz-and-gros-1185153", "source_name": "ACCESS Newswire", "published_at": "2026-07-08T06:41:51", "published_display": "08 Jul 2026 06:41", "sentiment": "negative", "sentiment_pct": 25, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros ...", "summary": "Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation (NASDAQ: OMER) following a significant stock price drop. The investigation stems from Omeros announcing that the European Medicines Agency's Committee for Medicinal Products for Human Use ", "url": "https://www.caledonianrecord.com/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-omeros/article_6888dcdb-2cf1-5eb5-afe2-670738ebee23.html", "source_name": "Caledonian Record", "published_at": "2026-07-07T22:09:23", "published_display": "07 Jul 2026 22:09", "sentiment": "negative", "sentiment_pct": 15, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Omeros Corporation (OMER) the Best Get Rich Quick Stock to Buy Right Now?", "summary": "Omeros Corporation (OMER) is highlighted as a top \"get rich quick\" stock despite a recent price target trim by H.C. Wainwright due to a \"disappointing\" CHMP opinion for Yartemlea. The analyst still maintains a Buy rating, viewing the U.S. Yartemlea launch as a key value driver. O", "url": "https://uk.finance.yahoo.com/news/omeros-corporation-omer-best-rich-055349381.html", "source_name": "Market source", "published_at": "2026-07-07T05:53:47", "published_display": "07 Jul 2026 05:53", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Corporation Files SEC Form 8-K for Other Events \u2013 Nasdaq: OMER, July 2026", "summary": "Omeros Corporation has filed an SEC Form 8-K announcing the repurchase of a significant portion of its 9.50% Convertible Senior Notes due 2029. The company plans to repurchase an initial $16.0 million for approximately $31.3 million and potentially an additional $14.5 million, re", "url": "https://www.minichart.com.sg/2026/07/06/omeros-corporation-files-sec-form-8-k-for-other-events-nasdaq-omer-july-2026/", "source_name": "Minichart", "published_at": "2026-07-06T14:37:00", "published_display": "06 Jul 2026 14:37", "sentiment": "positive", "sentiment_pct": 71, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros (NASDAQ: OMER) expands 2029 note repurchases and weighs new debt", "summary": "Omeros Corporation is repurchasing a significant portion of its 9.50% Convertible Senior Notes due 2029 to reduce costly debt. The company expects to complete an initial repurchase of $16.0 million in principal, leaving $54.8 million outstanding, and has agreed to repurchase an a", "url": "https://www.stocktitan.net/sec-filings/OMER/8-k-omeros-corp-reports-material-event-4fdf54084e77.html", "source_name": "Stock Titan", "published_at": "2026-07-06T12:11:20", "published_display": "06 Jul 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Omeros Corporation (OMER) And Encourages Stockholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Omeros Corporation (OMER) following a significant stock price drop. The investigation comes after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative o", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-omeros-corpo-1185151", "source_name": "ACCESS Newswire", "published_at": "2026-07-05T18:40:44", "published_display": "05 Jul 2026 18:40", "sentiment": "negative", "sentiment_pct": 27, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Omeros Corporation \u2013 NASDAQ:OMER", "summary": "This article provides financial information for Omeros Corporation (NASDAQ: OMER), specifically focusing on its enterprise value to revenue forward metric. The content appears to be a stub or a section of a larger financial data page, showing a table header for \"Period,\" \"Value,\"", "url": "https://www.tradingview.com/symbols/NASDAQ-OMER/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T06:11:48", "published_display": "05 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Corporation Reports First Quarter 2026 Financial Results", "summary": "Omeros Corporation announced its first-quarter 2026 financial results, reporting net income of $56.1 million, or $0.78 per share, a significant improvement from a net loss in the prior year. This turnaround was driven by the commercial launch of YARTEMLEA\u00ae in January 2026, which ", "url": "https://natlawreview.com/press-releases/omeros-corporation-reports-first-quarter-2026-financial-results", "source_name": "The National Law Review", "published_at": "2026-07-04T07:10:53", "published_display": "04 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER", "summary": "Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation (NASDAQ: OMER) following a significant stock price drop. The investigation began after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negati", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-omeros-corporation---omer-302816386.html", "source_name": "PR Newswire", "published_at": "2026-07-02T00:10:15", "published_display": "02 Jul 2026 00:10", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros stock drops 19% after EU rejects key drug application, prompting fraud investigation", "summary": "Omeros Corporation's stock dropped 19.12% after the European Medicines Agency's committee issued a negative opinion on its drug narsoplimab. This rejection led to an investigation by Pomerantz LLP into potential securities fraud against Omeros and its executives. The development ", "url": "https://pluang.com/en/news-feed/peringatan-investor-pomerantz-litigasi-terhadap-omeros-corporation", "source_name": "Pluang", "published_at": "2026-07-02T00:10:15", "published_display": "02 Jul 2026 00:10", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Omeros Corporation \u2013 NASDAQ:OMER", "summary": "This article provides financial information for Omeros Corporation (NASDAQ: OMER), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of publication, with no trades recorded. The content is presented within the contex", "url": "https://www.tradingview.com/symbols/NASDAQ-OMER/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T14:09:21", "published_display": "28 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Omeros Corporation \u2013 BX:3O8", "summary": "The article focuses on the \"Price to earnings forward\" metric for Omeros Corporation (BX:3O8), listed on BX Swiss. It presents an overview of financial data for the company, indicating that the market was closed at the time of publication with no trades.", "url": "https://www.tradingview.com/symbols/BX-3O8/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T10:40:35", "published_display": "28 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide", "summary": "Omeros Corporation's narsoplimab, branded as Yartemlea, received a negative opinion from the European Medicines Agency's Human Medicines Committee (CHMP) for its stem cell transplant-associated thrombotic microangiopathy treatment. This contrasts with its approval by the U.S. FDA", "url": "https://www.sahmcapital.com/news/content/fda-approved-europe-unconvinced-omeros-stem-cell-transplant-treatment-hits-regulatory-divide-2026-06-26", "source_name": "Sahm", "published_at": "2026-06-28T03:39:06", "published_display": "28 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Omeros Corporation \u2013 NASDAQ:OMER", "summary": "This article focuses on the enterprise value to EBITDA forward metric for Omeros Corporation (NASDAQ: OMER). It is a financial data point presented within the context of a market analysis platform, likely TradingView, indicating a key valuation ratio for the pharmaceutical compan", "url": "https://www.tradingview.com/symbols/NASDAQ-OMER/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T02:36:30", "published_display": "28 Jun 2026 02:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Omeros Corporation \u2013 BX:3O8", "summary": "This page from TradingView provides financial information for Omeros Corporation (BX:3O8), specifically focusing on its price-to-book forward ratio. It highlights that the market for this stock is currently closed with no trades. The site also lists various tools and services off", "url": "https://www.tradingview.com/symbols/BX-3O8/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:39:30", "published_display": "28 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Omeros Corporation \u2013 NASDAQ:OMER", "summary": "The article provides a financial overview of Omeros Corporation (NASDAQ: OMER), specifically focusing on its Price to Sales (forward) metric. It mentions the stock is listed on Nasdaq and that the market was closed at the time of publication, with no trades. The content is primar", "url": "https://www.tradingview.com/symbols/NASDAQ-OMER/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:08:49", "published_display": "27 Jun 2026 05:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros stock crashes on regulatory setback: buy the dip?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNYnlqajRaZEczOFZVVUg0TTRFX1V3NWRkLTg5OU5iVEJMT1BzbWo1LW1PMS1nc1FWZ0JjY2tUNFl0ZEpVbFBmUzVRWG9wb2JoUHc2cU1fLVVuMUhJTmN6aHp0X2JLYmZmcVhaSktwZGcxXy1QeGY2bUlGZ3RqWUU3Y1h6UWxSNXNwTUU0SGo4UmtMN3ZkdHhMVQ?oc=5", "source_name": "Invezz", "published_at": "2026-06-26T18:20:36+00:00", "published_display": "26 Jun 2026 18:20", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European regulator issues negative opinion on Omeros\u2019 TA-TMA drug", "summary": "The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a negative opinion on Omeros Corporation's marketing authorization application for narsoplimab, a drug to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-T", "url": "https://www.investing.com/news/company-news/european-regulator-issues-negative-opinion-on-omeros-tatma-drug-93CH-4762774", "source_name": "Investing.com", "published_at": "2026-06-26T14:40:37", "published_display": "26 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros to Seek EMA Review After Negative Opinion on Narsoplimab Marketing Application", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/omeros-seek-ema-review-negative-130053475.html", "source_name": "MT Newswires", "published_at": "2026-06-26T13:00:53+00:00", "published_display": "26 Jun 2026 13:00", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA", "summary": "Omeros Corporation announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on its marketing authorization application for narsoplimab (YARTEMLEA\u00ae) for treating hematopoietic stem cell transplant-associat", "url": "https://www.biospace.com/press-releases/omeros-corporation-announces-update-on-european-marketing-authorization-application-for-narsoplimab-in-ta-tma", "source_name": "BioSpace", "published_at": "2026-06-26T13:40:37", "published_display": "26 Jun 2026 13:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros drops amid EU hurdle for transplant drug (OMER:NASDAQ)", "summary": "Omeros (OMER) shares dropped significantly in premarket trading after an expert panel of the EU drug regulator, the European Medicines Agency, declined to endorse the company's transplant therapy, narsoplimab. The Seattle-based biotech company released a statement regarding this ", "url": "https://seekingalpha.com/news/4607732-omeros-drops-amid-eu-hurdle-transplant-drug", "source_name": "Seeking Alpha", "published_at": "2026-06-26T12:54:51", "published_display": "26 Jun 2026 12:54", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros stock tumbles after EMA panel rejects narsoplimab application", "summary": "Omeros Corporation shares fell significantly after a European Medicines Agency (EMA) panel issued a negative opinion on its marketing authorization application for narsoplimab, a drug for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Despite t", "url": "https://www.investing.com/news/stock-market-news/omeros-stock-tumbles-after-ema-panel-rejects-narsoplimab-application-93CH-4762819", "source_name": "Investing.com", "published_at": "2026-06-26T12:40:37", "published_display": "26 Jun 2026 12:40", "sentiment": "negative", "sentiment_pct": 27, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is OMER Stock Falling Today?", "summary": "Omeros Corporation (OMER) stock is falling today after European regulators issued a negative opinion on its therapy, Yartemlea, for hematopoietic stem cell transplant-associated thrombotic microangiopathy. The European Medicines Agency (EMA) found insufficient evidence of the dru", "url": "https://stocktwits.com/news-articles/markets/equity/why-is-omer-stock-falling-today-june-26-2026/cZ1cF1ER7gV", "source_name": "Stocktwits", "published_at": "2026-06-26T12:39:51", "published_display": "26 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Omeros stock tumbling today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNQndYei0tT0RQZzd2emE3RGtNSFR6SkhQaEk4V19IUlF1UmJReklFZTFVWV9XV3lBWlEzUlpfYmRoYzlJSWNPb1pTd0NkOERJZzJtRVl2dlpURjVyR2s3dHBGYi02bHRuT3BLVmZMb3pua2Zja3lWaVZCWTFRRzdEOWV6b2FHSEtKU3d3Q0RNV1hLMDlwTHFnTWRGZEI?oc=5", "source_name": "Investing.com", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros EU review turns negative on rare transplant complication drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPTnlqdWhfSGlUbzFmRV9VZUdpTTVQLVhfeXNEcXlhd3oycGEzdC1Vd21FMXNsdTQ0S0gtUFpRYmpnTElRNDdxaUR4UDM2TTRMWUtDV0VrOTQzLVE2T1ViZ2JaZWNlcmtlUTV6QUwtSTV4czhoQXJYb0ZGVzJsSnc2ZDV6OVhKSUFaTkQzWHRmaUd1NVF1aXVCdmdLNmp3cFRUMXd6dHp5Z3NCb0JXQ2pqQ3ZR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] OMEROS CORP Reports Material Event", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOcmwwOVJ6OV9ISVhoX3JxVU05U0VoajVUYjNtWDloMEh0ZEpMQVNhcWl5TVlNN29Ud25PY1B1OUlEU1NtUnN3UEo5TldjZDFhLXgtMHdoS3FlNVF5Ql96U0lMcThJS1FyRmozS3YyNlRTZEZPTWx6ZkhhNWgtQkRfLWJUSkxkMkF5QW1iMGszYXQ3allTVjBBNDZaMDZFMDFfanc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/baf8677c-50e5-383a-96a6-c0fa660575f3/novocure-vs.-omeros%3A-which.html", "source_name": "Motley Fool", "published_at": "2026-06-22T14:59:30+00:00", "published_display": "22 Jun 2026 14:59", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros (NASDAQ: OMER) director receives 15,000-share stock option grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQTGFhM3FqUkk0bHNjVkN3al9NdXI0VldFaVFENWQ1UkZDWnVOSkU0dVBoY0l6UWxnQ2kzYnd0aXhQcFA0dkI3NEVaZFFoZVctb2toWE8wa1pZSHRnZVFnZ1llOHFlemVOY2lrRnlxeGlmM1NnSnlvemhyeW1CNWpPNXRQUlcyMGxaZW5QNTdxT3pRZW50NmJrcm5FNzJxUVJwbGxrdjd2MXo?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros (NASDAQ: OMER) director Leroy Hood granted 15,000 stock options at $10.28", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQV1FsOVBnVVlXWUNRSG14SWoyT0tyTFhqcnBLc2E4MFlEdmNDMXNRS2p1TDlUbXZhUDBCajRSZU9NRHYxZWlfS2wzQnBnd3IyOTgzVkkzbnJuaEYxOW9SRWJvek1QYi1lZ0dpVGhsOTJHRmxXRlBkQ3lFNU9mV0dUOW9kNmNiOGs0Z0VYWTJqYVNJemZsRnJrNjJnR3RhMlFfajFrZkZXZmI?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros (NASDAQ: OMER) director receives 15,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNMTNOdkZ3QXlzMzdnejIxNFhaQ3BNQXRsbm1WQ2J1SG1renMtX3pUSWN3MVB3LVk2b2NRMElleUt0a3FZVFA0MUtiRkRyZXpCQ2VhN3J0NVpRU1h1Nmp1VlpHaFVZNXpRUzdDWjZfZ2FTR0dJZE50a1ZxcWpUWHNZVWl0SDE5ODZGSnMwX2oyaGxvRmZZUmdGM2xXcEoxbl9ITm9qV1lTNXo?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNMk1JaFU3SU5iY2xJeHluektfX1hrTVh3ZEdUSGU2SDg4MzAxWUVUNXFWWXFhNEgxR0VFb1NsamVuYk5Ka2tVMnI3dnlIR21OWEh3dVBWWERhOFpxZlRORU1tSmFfVU9DT0VoejZIbnptQmx6bzQ4OUszRGVCa0czNU1nRHRYdlY0VlAzUFk5R0ZXbDRwVWlQSHNfMXJwZm02QnBDVndzWmJoU2RxLUp4TmRnbTU1Yl9YYWdxd254dXJ0T2hzdGdXTUxUSER1NjV1Y2dB?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros (NASDAQ: OMER) plans $16.0M buyback of 9.50% 2029 convertible notes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPa3JDdEVpTmlPa2hnQkViUU5fQmwzOUlFWVJVcnFLUkdqOFRQRGhrRTlSb0ZXaVVxVlVQQWlBaVJtZFhEN1pScU01M1lCZ3pwSVZod0ZnczdoTV9BWjlObGxOX1lodTVNWjl3V09nZER6bC01R3Q5S0NnbzFnZlJ6OHBOTHNMTUV6NlJaa1B4WkM1RUJlR1lJVmlGWTZSYURIR0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Announces Webcast Details for Annual Meeting of Shareholders", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/omeros-announces-webcast-details-annual-123000123.html", "source_name": "Business Wire", "published_at": "2026-06-15T12:30:00+00:00", "published_display": "15 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Omeros shareholders can join the June 18 virtual annual meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPRmx1TGtBa2QxWlBCaHc4T0ZsTGkzcWJBU3lYWFRlcm9pLUU0SnVTSnhvZV94aXI2QzRFVDRmNjJvRWF2OVFLbFNLV2poaEF2UUZ1bFB6WXcxNTBWOFdLd0NQQXJlWU9YWV84a3NCWDZwNXZ1WDViSG95UTA2M2ZudWNnZFJMV2dPTTJja1AxdDc2ZzYtNkFSVnlob2EtSThoWU9LczFOOWVaeDNVc3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros (OMER) Q1 Profit Of US$51.2 Million Tests One Off Gain Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How Omeros\u2019 (OMER) Noncash-Boosted Q1 Profit Swing Will Impact Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQa1Z1UTNsQ3otb0Jra2JLZHg2ZkljX2tSZzVKOG5FRFFQc1IyX0Q3VFZjdm00ZGNhU2lhSHdHZzhWVHpMaHV3c1dLZEpLUXBtb3kxeE5icnZlZVFiUHRCS2dxTnJHT3NxZDY5Y01WTVhOQ1c4aFVYdTBZUkNCbFJaQmpEWkpXU3Q5OVZjNGF2VEkzLXRqMG5taHkzLXdYNlFxeUZTZVQwQURBaDdJRG9KT0Z5SkNWaHNjTDFOVnZ0cFYwR05mM1p3bUk3dnBJSkdTMzNkOUtn0gHbAUFVX3lxTFBOWnJzd09uSGg4UnYybW45SGx5MnctMmdMcWliVjFUTEhST1RfS1NfbVhQN2xRLWVndV9XZTBjcXB5YWRYOVJmamM4dlJyOEpfT0VWRE53TlMtdWpzbEhNd1prUGNRdF9vZERNSy1VMXl1WVFlczNTZ2dkbnc3Y3RVWTNGU0FNV2RTdEZ0QkFhS1NPV3Y0RWh0RXpkUkd3V3h2UVhKQ2djLTI0TXhJcTRiNWpTTUZQNVBfVThtY2s0ME1HOWJ2ZkNXdWd4ZE5wZVExTkJWWEwyRmlhUQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Omeros (OMER) Valuation After Recent Share Price Rebound And Novo Nordisk Deal Prospects", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Omeros (OMER) is a Great Momentum Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPbTJZeS03Rng2NmkxeldiejhVanQ5U3pXYzJzQ0hucGd4bG5CajBzemNBcktsZGVGVERmbV9jV2dRMktSQVR1b29Ca0lpM0ZiREl0N0p3NGNyS0JldlJFb2s5Q1BWVU44ck1yTVJ3aU9CemxObFZjTW1kMFBmUGRGM1Z5Mmp1Uy1KRkxpeVdEbXhqeVcxSnNJ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "After $240M Novo deal, Omeros launches first approved TA-TMA drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxObkl0Y0lQNzkxcTBJV25qNllLRm80T1pCV0FGbkg2ZnhEcS1JRDQyS0wza2hUODlxXzltZkE5MnkxSjFxZWpTVWNyMkRfbVpORnhWWExyOTZncGthZzBPOWVKOEFWdmFlTHdUU3BRQ0tKeXdPRnQ2NmdxUXhiZlJ4ZHlqUDRwMmVESGdJWDZLOXNVSW9rOG5UT29tZmxYWWtRalZfbkwxVTZzYjUyNkU5eGIxa2E?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Did Omeros Stock Jump 5% In After-Hours Trading Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNUk51dllWR1BobFBNcnNzbm9fZ04zRmdHTW5XSWQ3aW1uVVBnLXVrOGxsWV9Dcy1RUXdCZC1GY3VLZjhDNkVULU9seUxHQk53bkFNeE9YRi1xRUxPSEpyd184WXF0dXlHUzhlY1ZJVkF3ZXVOZUJMc2d5eV9lV2JHeGE3cmhndVROYk5ISGNuRmRMSF9XU09aaXNYa3NuVVV6SXhaOUtxSkZrQ1JyY3Y1SllwbmhSeUFiTEhpRQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros: Why The Novo Nordisk Deal Is More Important Than FDA Approval (Rating Upgrade)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOSmliR0RLUlJFdGZ5SEhJdGlqYlRBOVY1QmkzWWFPQVFCV3ZwaDZPWExlc1FHLThFbjZUTXJ4dnpSc2JUN3VZeVRDRGpwY0FZQmw3c09aVW03LTNIY2VLdFRnYk9QZkFMMU9WbzBLNmx4dkNDY1h4QWJsb21JTzdtWnpMQjZXTFMwR0F3ZE1oRE95a2hxZ2kxSEdqMmJhWG01Szh4cmpPVTJ2Q3hGc18wdm5IZHlkT0kzeW1tN213?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-29T08:00:00+00:00", "published_display": "29 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQYmk1VE1zb3FPNlBadlV0MDZDSUM2Z25mRWszSGNjS19KWjFCQ09TQllRaGdmSUw3T1Bwc0VfRkVCLUFSbXB0Tzg1YkJUUkwtalJleXFRUjJyeGJvbmpNM3N4dXhpMDFJckR1eWtlNkJtNFRDbURQeGVIQ1FJWHMxaU14ZExwSEk?oc=5", "source_name": "Market source", "published_at": "2025-12-29T08:00:00+00:00", "published_display": "29 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Omeros' drug to treat dangerous transplant complication", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPaVlCY2RiNUYzTHItSVAtV3dvLU9fdDNsSW5UTEVHTURNMEVvT0d0M2U3NGFBeXFzaERCT05HbC1WemJKTVAyLVRYUTg1cDRMZXQyTjRqZjV1TFF2RUZ6MG1WMmFBZjI1cnhNSlI3Zm1FbHUwTTlIMVYzV3NPM3lpN0NZYUZ3ZVV2ZXBRMm5adFRrWDI2b243bloxdXhzN0NqSHFRNHZpb0pDT1A2cFZOWXN1N29VOTExUmJoYklHRkhycGdoMnQtd2o5Y3U4QVUweDR3V0Jn?oc=5", "source_name": "Reuters", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Stock Garners High Retail Attention Ahead Of FDA Verdict For Life-Saving Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQenhBemhCVTBwcVRFeHVjN3dFakxBVXZhWkNDWFAzSmVTZm5LNUJaWDNoeVZVdERYOVNqMFBqYkU3Zmp4WHhwdGNwUm13V2ZDM1RtUDBjS3pLTEV3YU5VS01LLXg3MG9LWHZnSU5Pd3hWeE1ZZ2ZjQWdERi1qMGxOdUlJN0NTOG5NMDVVOE5ZMTd4QW5hNFRCUGpYMkNPRHNmQ0JWN2FCZkwzWFhhWWJF?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal \u2014 Retail Shifts Focus To Narsoplimab FDA Call", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxOMUZlbEZ3YmwxdGx0WW80TGJPQW1HRGNWaTdFQ2I0UURuQ05jT2VwMFJZYlFGYmtUQXh3bWdhSzZkZXcwNndmb3VtN25rUi16bUw2WGdKNlRRNXB1Z1AzMWJZQzRkZ0pEd0x3aHo3NlNQVlZtNzJJRXFNU0F2ak8tcjNTUUxfSlUzZXVzVE1fbWc3VFdXNnhKLUtsV0JfTUlWN09UTXhqdndtdVVBNEowbEozTG1aYXd4OGU5LWdONTlXNU5ZSXN5S3l3UVBVcVBoeWNDV19pMG1TX0lJWE9JZGtwZEZiVXktcVlYVmYwNVlZRHZzN1Nka0ZiYXJCT21XalNDSw?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-01T08:00:00+00:00", "published_display": "01 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNVGdpcWJ6Vi16ZU5fXzJRNlowRHcyblJ6R0ZKOFhGaEw5RDFVa2tyejExWllpWnZ4MWl5d25uOGlGSEd5WGZXYWhmclJtUmQxMXpURzhrVHg5a0xaV0F1QTduLTRlTWljSUxJLTdkV05SYzE1bWRuWkZibWx6WlRFVjJ2U3IyM181NGJ4czZzSndhYkZCelJHVHBBTQ?oc=5", "source_name": "Market source", "published_at": "2026-07-15T15:43:00+00:00", "published_display": "15 Jul 2026 15:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (OMER)", "summary": "Omeros Corporation (OMER) is experiencing weak near-term sentiment despite long-term strength, with its support levels currently being tested. AI models have generated three trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014tailored to different risk profiles, alon", "url": "https://news.stocktradersdaily.com/news_release/149/Understanding_Momentum_Shifts_in_OMER_071526034002_1784144402.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-15T15:44:09", "published_display": "15 Jul 2026 15:44", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros stock drops 19% after EU rejects key drug application, prompting investor lawsuit.", "summary": "Omeros Corporation's stock dropped 19.12% after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on its drug narsoplimab. This rejection led to Pomerantz LLP launching a securities fraud investigation on behalf of Ome", "url": "https://pluang.com/en/news-feed/peringatan-investor-pomerantz-litigasi-atas-omeros-corporation-omer", "source_name": "Pluang", "published_at": "2026-07-14T22:42:21", "published_display": "14 Jul 2026 22:42", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Corporation Investigated by the Portnoy Law Firm", "summary": "The Portnoy Law Firm has launched an investigation into Omeros Corporation (NASDAQ: OMER) for potential securities fraud and may file a class action lawsuit. This follows a significant 19.12% drop in Omeros's stock price after the European Medicines Agency's committee issued a ne", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326415/0/en/omeros-corporation-investigated-by-the-portnoy-law-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T14:41:02", "published_display": "13 Jul 2026 14:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNRWZyQlAyZjdENUtsVUtLbXpDYml3aFhDZXg4c01hTEdDSjFjLTZ5YUVnU2NvcW9wYmo0cTNSb3NQZUVpOTFYVVFtQVRDS3VKeDRDTzROcTZwQjhDOGk2c2RFWWZEUGl5OUxxeXBJRmFvU1JGRnZDNVFhSzNZM2FMZ0prRFR6MHpobjJyTGJlNlpDOE82dXQxWmhwRy1lX0ZDQlowVE45VlV6aGMyVktXMHlJRVRWMW1DMTM0ZEoySWJoaVNQYkVUYw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-07-08T22:21:00+00:00", "published_display": "08 Jul 2026 22:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm", "summary": "The Schall Law Firm is investigating Omeros Corporation (NASDAQ: OMER) on behalf of investors for potential securities law violations. This follows Omeros's announcement on June 26, 2026, that the European Medicines Agency's CHMP issued a negative opinion on its marketing authori", "url": "https://www.globenewswire.com/news-release/2026/07/08/3324190/0/en/omer-investors-have-opportunity-to-join-omeros-corporation-fraud-investigation-with-the-schall-law-firm.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T19:39:39", "published_display": "08 Jul 2026 19:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros shares drop 19% after EMA rejects narsoplimab drug approval, triggering fraud probe.", "summary": "Shares of Omeros Corporation dropped over 19% after the European Medicines Agency's CHMP issued a negative opinion on its marketing authorization application for narsoplimab, a TA-TMA treatment. This rejection has prompted The Schall Law Firm to launch an investigation into wheth", "url": "https://pluang.com/en/news-feed/investor-omeros-ikut-penyelidikan-kasus-penipuan", "source_name": "Pluang", "published_at": "2026-07-08T17:11:01", "published_display": "08 Jul 2026 17:11", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Corporation (OMER) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Omeros Corporation (NASDAQ:OMER) purchasers following a significant drop in its stock price. This decline occurred after the Committee for Medicinal Products for Human Use (CHMP) of the European Med", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/omeros-corporation-omer-investigation-bronstein-gewirtz-and-gros-1185153", "source_name": "ACCESS Newswire", "published_at": "2026-07-08T06:41:51", "published_display": "08 Jul 2026 06:41", "sentiment": "negative", "sentiment_pct": 25, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros ...", "summary": "Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation (NASDAQ: OMER) following a significant stock price drop. The investigation stems from Omeros announcing that the European Medicines Agency's Committee for Medicinal Products for Human Use ", "url": "https://www.caledonianrecord.com/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-omeros/article_6888dcdb-2cf1-5eb5-afe2-670738ebee23.html", "source_name": "Caledonian Record", "published_at": "2026-07-07T22:09:23", "published_display": "07 Jul 2026 22:09", "sentiment": "negative", "sentiment_pct": 15, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Omeros Corporation (OMER) the Best Get Rich Quick Stock to Buy Right Now?", "summary": "Omeros Corporation (OMER) is highlighted as a top \"get rich quick\" stock despite a recent price target trim by H.C. Wainwright due to a \"disappointing\" CHMP opinion for Yartemlea. The analyst still maintains a Buy rating, viewing the U.S. Yartemlea launch as a key value driver. O", "url": "https://uk.finance.yahoo.com/news/omeros-corporation-omer-best-rich-055349381.html", "source_name": "Market source", "published_at": "2026-07-07T05:53:47", "published_display": "07 Jul 2026 05:53", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Corporation Files SEC Form 8-K for Other Events \u2013 Nasdaq: OMER, July 2026", "summary": "Omeros Corporation has filed an SEC Form 8-K announcing the repurchase of a significant portion of its 9.50% Convertible Senior Notes due 2029. The company plans to repurchase an initial $16.0 million for approximately $31.3 million and potentially an additional $14.5 million, re", "url": "https://www.minichart.com.sg/2026/07/06/omeros-corporation-files-sec-form-8-k-for-other-events-nasdaq-omer-july-2026/", "source_name": "Minichart", "published_at": "2026-07-06T14:37:00", "published_display": "06 Jul 2026 14:37", "sentiment": "positive", "sentiment_pct": 71, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros (NASDAQ: OMER) expands 2029 note repurchases and weighs new debt", "summary": "Omeros Corporation is repurchasing a significant portion of its 9.50% Convertible Senior Notes due 2029 to reduce costly debt. The company expects to complete an initial repurchase of $16.0 million in principal, leaving $54.8 million outstanding, and has agreed to repurchase an a", "url": "https://www.stocktitan.net/sec-filings/OMER/8-k-omeros-corp-reports-material-event-4fdf54084e77.html", "source_name": "Stock Titan", "published_at": "2026-07-06T12:11:20", "published_display": "06 Jul 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Omeros Corporation (OMER) And Encourages Stockholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Omeros Corporation (OMER) following a significant stock price drop. The investigation comes after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative o", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-omeros-corpo-1185151", "source_name": "ACCESS Newswire", "published_at": "2026-07-05T18:40:44", "published_display": "05 Jul 2026 18:40", "sentiment": "negative", "sentiment_pct": 27, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Omeros Corporation \u2013 NASDAQ:OMER", "summary": "This article provides financial information for Omeros Corporation (NASDAQ: OMER), specifically focusing on its enterprise value to revenue forward metric. The content appears to be a stub or a section of a larger financial data page, showing a table header for \"Period,\" \"Value,\"", "url": "https://www.tradingview.com/symbols/NASDAQ-OMER/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T06:11:48", "published_display": "05 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Corporation Reports First Quarter 2026 Financial Results", "summary": "Omeros Corporation announced its first-quarter 2026 financial results, reporting net income of $56.1 million, or $0.78 per share, a significant improvement from a net loss in the prior year. This turnaround was driven by the commercial launch of YARTEMLEA\u00ae in January 2026, which ", "url": "https://natlawreview.com/press-releases/omeros-corporation-reports-first-quarter-2026-financial-results", "source_name": "The National Law Review", "published_at": "2026-07-04T07:10:53", "published_display": "04 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER", "summary": "Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation (NASDAQ: OMER) following a significant stock price drop. The investigation began after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negati", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-omeros-corporation---omer-302816386.html", "source_name": "PR Newswire", "published_at": "2026-07-02T00:10:15", "published_display": "02 Jul 2026 00:10", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros stock drops 19% after EU rejects key drug application, prompting fraud investigation", "summary": "Omeros Corporation's stock dropped 19.12% after the European Medicines Agency's committee issued a negative opinion on its drug narsoplimab. This rejection led to an investigation by Pomerantz LLP into potential securities fraud against Omeros and its executives. The development ", "url": "https://pluang.com/en/news-feed/peringatan-investor-pomerantz-litigasi-terhadap-omeros-corporation", "source_name": "Pluang", "published_at": "2026-07-02T00:10:15", "published_display": "02 Jul 2026 00:10", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Omeros Corporation \u2013 NASDAQ:OMER", "summary": "This article provides financial information for Omeros Corporation (NASDAQ: OMER), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of publication, with no trades recorded. The content is presented within the contex", "url": "https://www.tradingview.com/symbols/NASDAQ-OMER/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T14:09:21", "published_display": "28 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Omeros Corporation \u2013 BX:3O8", "summary": "The article focuses on the \"Price to earnings forward\" metric for Omeros Corporation (BX:3O8), listed on BX Swiss. It presents an overview of financial data for the company, indicating that the market was closed at the time of publication with no trades.", "url": "https://www.tradingview.com/symbols/BX-3O8/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T10:40:35", "published_display": "28 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide", "summary": "Omeros Corporation's narsoplimab, branded as Yartemlea, received a negative opinion from the European Medicines Agency's Human Medicines Committee (CHMP) for its stem cell transplant-associated thrombotic microangiopathy treatment. This contrasts with its approval by the U.S. FDA", "url": "https://www.sahmcapital.com/news/content/fda-approved-europe-unconvinced-omeros-stem-cell-transplant-treatment-hits-regulatory-divide-2026-06-26", "source_name": "Sahm", "published_at": "2026-06-28T03:39:06", "published_display": "28 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Omeros Corporation \u2013 NASDAQ:OMER", "summary": "This article focuses on the enterprise value to EBITDA forward metric for Omeros Corporation (NASDAQ: OMER). It is a financial data point presented within the context of a market analysis platform, likely TradingView, indicating a key valuation ratio for the pharmaceutical compan", "url": "https://www.tradingview.com/symbols/NASDAQ-OMER/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T02:36:30", "published_display": "28 Jun 2026 02:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Omeros Corporation \u2013 BX:3O8", "summary": "This page from TradingView provides financial information for Omeros Corporation (BX:3O8), specifically focusing on its price-to-book forward ratio. It highlights that the market for this stock is currently closed with no trades. The site also lists various tools and services off", "url": "https://www.tradingview.com/symbols/BX-3O8/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:39:30", "published_display": "28 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Omeros Corporation \u2013 NASDAQ:OMER", "summary": "The article provides a financial overview of Omeros Corporation (NASDAQ: OMER), specifically focusing on its Price to Sales (forward) metric. It mentions the stock is listed on Nasdaq and that the market was closed at the time of publication, with no trades. The content is primar", "url": "https://www.tradingview.com/symbols/NASDAQ-OMER/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:08:49", "published_display": "27 Jun 2026 05:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros stock crashes on regulatory setback: buy the dip?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNYnlqajRaZEczOFZVVUg0TTRFX1V3NWRkLTg5OU5iVEJMT1BzbWo1LW1PMS1nc1FWZ0JjY2tUNFl0ZEpVbFBmUzVRWG9wb2JoUHc2cU1fLVVuMUhJTmN6aHp0X2JLYmZmcVhaSktwZGcxXy1QeGY2bUlGZ3RqWUU3Y1h6UWxSNXNwTUU0SGo4UmtMN3ZkdHhMVQ?oc=5", "source_name": "Invezz", "published_at": "2026-06-26T18:20:36+00:00", "published_display": "26 Jun 2026 18:20", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European regulator issues negative opinion on Omeros\u2019 TA-TMA drug", "summary": "The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a negative opinion on Omeros Corporation's marketing authorization application for narsoplimab, a drug to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-T", "url": "https://www.investing.com/news/company-news/european-regulator-issues-negative-opinion-on-omeros-tatma-drug-93CH-4762774", "source_name": "Investing.com", "published_at": "2026-06-26T14:40:37", "published_display": "26 Jun 2026 14:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros to Seek EMA Review After Negative Opinion on Narsoplimab Marketing Application", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/omeros-seek-ema-review-negative-130053475.html", "source_name": "MT Newswires", "published_at": "2026-06-26T13:00:53+00:00", "published_display": "26 Jun 2026 13:00", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA", "summary": "Omeros Corporation announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on its marketing authorization application for narsoplimab (YARTEMLEA\u00ae) for treating hematopoietic stem cell transplant-associat", "url": "https://www.biospace.com/press-releases/omeros-corporation-announces-update-on-european-marketing-authorization-application-for-narsoplimab-in-ta-tma", "source_name": "BioSpace", "published_at": "2026-06-26T13:40:37", "published_display": "26 Jun 2026 13:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros drops amid EU hurdle for transplant drug (OMER:NASDAQ)", "summary": "Omeros (OMER) shares dropped significantly in premarket trading after an expert panel of the EU drug regulator, the European Medicines Agency, declined to endorse the company's transplant therapy, narsoplimab. The Seattle-based biotech company released a statement regarding this ", "url": "https://seekingalpha.com/news/4607732-omeros-drops-amid-eu-hurdle-transplant-drug", "source_name": "Seeking Alpha", "published_at": "2026-06-26T12:54:51", "published_display": "26 Jun 2026 12:54", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros stock tumbles after EMA panel rejects narsoplimab application", "summary": "Omeros Corporation shares fell significantly after a European Medicines Agency (EMA) panel issued a negative opinion on its marketing authorization application for narsoplimab, a drug for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Despite t", "url": "https://www.investing.com/news/stock-market-news/omeros-stock-tumbles-after-ema-panel-rejects-narsoplimab-application-93CH-4762819", "source_name": "Investing.com", "published_at": "2026-06-26T12:40:37", "published_display": "26 Jun 2026 12:40", "sentiment": "negative", "sentiment_pct": 27, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is OMER Stock Falling Today?", "summary": "Omeros Corporation (OMER) stock is falling today after European regulators issued a negative opinion on its therapy, Yartemlea, for hematopoietic stem cell transplant-associated thrombotic microangiopathy. The European Medicines Agency (EMA) found insufficient evidence of the dru", "url": "https://stocktwits.com/news-articles/markets/equity/why-is-omer-stock-falling-today-june-26-2026/cZ1cF1ER7gV", "source_name": "Stocktwits", "published_at": "2026-06-26T12:39:51", "published_display": "26 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Omeros stock tumbling today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNQndYei0tT0RQZzd2emE3RGtNSFR6SkhQaEk4V19IUlF1UmJReklFZTFVWV9XV3lBWlEzUlpfYmRoYzlJSWNPb1pTd0NkOERJZzJtRVl2dlpURjVyR2s3dHBGYi02bHRuT3BLVmZMb3pua2Zja3lWaVZCWTFRRzdEOWV6b2FHSEtKU3d3Q0RNV1hLMDlwTHFnTWRGZEI?oc=5", "source_name": "Investing.com", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros EU review turns negative on rare transplant complication drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPTnlqdWhfSGlUbzFmRV9VZUdpTTVQLVhfeXNEcXlhd3oycGEzdC1Vd21FMXNsdTQ0S0gtUFpRYmpnTElRNDdxaUR4UDM2TTRMWUtDV0VrOTQzLVE2T1ViZ2JaZWNlcmtlUTV6QUwtSTV4czhoQXJYb0ZGVzJsSnc2ZDV6OVhKSUFaTkQzWHRmaUd1NVF1aXVCdmdLNmp3cFRUMXd6dHp5Z3NCb0JXQ2pqQ3ZR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] OMEROS CORP Reports Material Event", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOcmwwOVJ6OV9ISVhoX3JxVU05U0VoajVUYjNtWDloMEh0ZEpMQVNhcWl5TVlNN29Ud25PY1B1OUlEU1NtUnN3UEo5TldjZDFhLXgtMHdoS3FlNVF5Ql96U0lMcThJS1FyRmozS3YyNlRTZEZPTWx6ZkhhNWgtQkRfLWJUSkxkMkF5QW1iMGszYXQ3allTVjBBNDZaMDZFMDFfanc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/baf8677c-50e5-383a-96a6-c0fa660575f3/novocure-vs.-omeros%3A-which.html", "source_name": "Motley Fool", "published_at": "2026-06-22T14:59:30+00:00", "published_display": "22 Jun 2026 14:59", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros (NASDAQ: OMER) director receives 15,000-share stock option grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQTGFhM3FqUkk0bHNjVkN3al9NdXI0VldFaVFENWQ1UkZDWnVOSkU0dVBoY0l6UWxnQ2kzYnd0aXhQcFA0dkI3NEVaZFFoZVctb2toWE8wa1pZSHRnZVFnZ1llOHFlemVOY2lrRnlxeGlmM1NnSnlvemhyeW1CNWpPNXRQUlcyMGxaZW5QNTdxT3pRZW50NmJrcm5FNzJxUVJwbGxrdjd2MXo?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros (NASDAQ: OMER) director Leroy Hood granted 15,000 stock options at $10.28", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQV1FsOVBnVVlXWUNRSG14SWoyT0tyTFhqcnBLc2E4MFlEdmNDMXNRS2p1TDlUbXZhUDBCajRSZU9NRHYxZWlfS2wzQnBnd3IyOTgzVkkzbnJuaEYxOW9SRWJvek1QYi1lZ0dpVGhsOTJHRmxXRlBkQ3lFNU9mV0dUOW9kNmNiOGs0Z0VYWTJqYVNJemZsRnJrNjJnR3RhMlFfajFrZkZXZmI?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros (NASDAQ: OMER) director receives 15,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNMTNOdkZ3QXlzMzdnejIxNFhaQ3BNQXRsbm1WQ2J1SG1renMtX3pUSWN3MVB3LVk2b2NRMElleUt0a3FZVFA0MUtiRkRyZXpCQ2VhN3J0NVpRU1h1Nmp1VlpHaFVZNXpRUzdDWjZfZ2FTR0dJZE50a1ZxcWpUWHNZVWl0SDE5ODZGSnMwX2oyaGxvRmZZUmdGM2xXcEoxbl9ITm9qV1lTNXo?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNMk1JaFU3SU5iY2xJeHluektfX1hrTVh3ZEdUSGU2SDg4MzAxWUVUNXFWWXFhNEgxR0VFb1NsamVuYk5Ka2tVMnI3dnlIR21OWEh3dVBWWERhOFpxZlRORU1tSmFfVU9DT0VoejZIbnptQmx6bzQ4OUszRGVCa0czNU1nRHRYdlY0VlAzUFk5R0ZXbDRwVWlQSHNfMXJwZm02QnBDVndzWmJoU2RxLUp4TmRnbTU1Yl9YYWdxd254dXJ0T2hzdGdXTUxUSER1NjV1Y2dB?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros (NASDAQ: OMER) plans $16.0M buyback of 9.50% 2029 convertible notes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPa3JDdEVpTmlPa2hnQkViUU5fQmwzOUlFWVJVcnFLUkdqOFRQRGhrRTlSb0ZXaVVxVlVQQWlBaVJtZFhEN1pScU01M1lCZ3pwSVZod0ZnczdoTV9BWjlObGxOX1lodTVNWjl3V09nZER6bC01R3Q5S0NnbzFnZlJ6OHBOTHNMTUV6NlJaa1B4WkM1RUJlR1lJVmlGWTZSYURIR0E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Announces Webcast Details for Annual Meeting of Shareholders", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/omeros-announces-webcast-details-annual-123000123.html", "source_name": "Business Wire", "published_at": "2026-06-15T12:30:00+00:00", "published_display": "15 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Omeros shareholders can join the June 18 virtual annual meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPRmx1TGtBa2QxWlBCaHc4T0ZsTGkzcWJBU3lYWFRlcm9pLUU0SnVTSnhvZV94aXI2QzRFVDRmNjJvRWF2OVFLbFNLV2poaEF2UUZ1bFB6WXcxNTBWOFdLd0NQQXJlWU9YWV84a3NCWDZwNXZ1WDViSG95UTA2M2ZudWNnZFJMV2dPTTJja1AxdDc2ZzYtNkFSVnlob2EtSThoWU9LczFOOWVaeDNVc3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros (OMER) Q1 Profit Of US$51.2 Million Tests One Off Gain Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Omeros\u2019 (OMER) Noncash-Boosted Q1 Profit Swing Will Impact Investors", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Omeros (OMER) Valuation After Recent Share Price Rebound And Novo Nordisk Deal Prospects", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Omeros (OMER) is a Great Momentum Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPbTJZeS03Rng2NmkxeldiejhVanQ5U3pXYzJzQ0hucGd4bG5CajBzemNBcktsZGVGVERmbV9jV2dRMktSQVR1b29Ca0lpM0ZiREl0N0p3NGNyS0JldlJFb2s5Q1BWVU44ck1yTVJ3aU9CemxObFZjTW1kMFBmUGRGM1Z5Mmp1Uy1KRkxpeVdEbXhqeVcxSnNJ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After $240M Novo deal, Omeros launches first approved TA-TMA drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxObkl0Y0lQNzkxcTBJV25qNllLRm80T1pCV0FGbkg2ZnhEcS1JRDQyS0wza2hUODlxXzltZkE5MnkxSjFxZWpTVWNyMkRfbVpORnhWWExyOTZncGthZzBPOWVKOEFWdmFlTHdUU3BRQ0tKeXdPRnQ2NmdxUXhiZlJ4ZHlqUDRwMmVESGdJWDZLOXNVSW9rOG5UT29tZmxYWWtRalZfbkwxVTZzYjUyNkU5eGIxa2E?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Omeros Stock Jump 5% In After-Hours Trading Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNUk51dllWR1BobFBNcnNzbm9fZ04zRmdHTW5XSWQ3aW1uVVBnLXVrOGxsWV9Dcy1RUXdCZC1GY3VLZjhDNkVULU9seUxHQk53bkFNeE9YRi1xRUxPSEpyd184WXF0dXlHUzhlY1ZJVkF3ZXVOZUJMc2d5eV9lV2JHeGE3cmhndVROYk5ISGNuRmRMSF9XU09aaXNYa3NuVVV6SXhaOUtxSkZrQ1JyY3Y1SllwbmhSeUFiTEhpRQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros: Why The Novo Nordisk Deal Is More Important Than FDA Approval (Rating Upgrade)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOSmliR0RLUlJFdGZ5SEhJdGlqYlRBOVY1QmkzWWFPQVFCV3ZwaDZPWExlc1FHLThFbjZUTXJ4dnpSc2JUN3VZeVRDRGpwY0FZQmw3c09aVW03LTNIY2VLdFRnYk9QZkFMMU9WbzBLNmx4dkNDY1h4QWJsb21JTzdtWnpMQjZXTFMwR0F3ZE1oRE95a2hxZ2kxSEdqMmJhWG01Szh4cmpPVTJ2Q3hGc18wdm5IZHlkT0kzeW1tN213?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-29T08:00:00+00:00", "published_display": "29 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQYmk1VE1zb3FPNlBadlV0MDZDSUM2Z25mRWszSGNjS19KWjFCQ09TQllRaGdmSUw3T1Bwc0VfRkVCLUFSbXB0Tzg1YkJUUkwtalJleXFRUjJyeGJvbmpNM3N4dXhpMDFJckR1eWtlNkJtNFRDbURQeGVIQ1FJWHMxaU14ZExwSEk?oc=5", "source_name": "Market source", "published_at": "2025-12-29T08:00:00+00:00", "published_display": "29 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Omeros' drug to treat dangerous transplant complication", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPaVlCY2RiNUYzTHItSVAtV3dvLU9fdDNsSW5UTEVHTURNMEVvT0d0M2U3NGFBeXFzaERCT05HbC1WemJKTVAyLVRYUTg1cDRMZXQyTjRqZjV1TFF2RUZ6MG1WMmFBZjI1cnhNSlI3Zm1FbHUwTTlIMVYzV3NPM3lpN0NZYUZ3ZVV2ZXBRMm5adFRrWDI2b243bloxdXhzN0NqSHFRNHZpb0pDT1A2cFZOWXN1N29VOTExUmJoYklHRkhycGdoMnQtd2o5Y3U4QVUweDR3V0Jn?oc=5", "source_name": "Reuters", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Stock Garners High Retail Attention Ahead Of FDA Verdict For Life-Saving Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQenhBemhCVTBwcVRFeHVjN3dFakxBVXZhWkNDWFAzSmVTZm5LNUJaWDNoeVZVdERYOVNqMFBqYkU3Zmp4WHhwdGNwUm13V2ZDM1RtUDBjS3pLTEV3YU5VS01LLXg3MG9LWHZnSU5Pd3hWeE1ZZ2ZjQWdERi1qMGxOdUlJN0NTOG5NMDVVOE5ZMTd4QW5hNFRCUGpYMkNPRHNmQ0JWN2FCZkwzWFhhWWJF?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal \u2014 Retail Shifts Focus To Narsoplimab FDA Call", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxOMUZlbEZ3YmwxdGx0WW80TGJPQW1HRGNWaTdFQ2I0UURuQ05jT2VwMFJZYlFGYmtUQXh3bWdhSzZkZXcwNndmb3VtN25rUi16bUw2WGdKNlRRNXB1Z1AzMWJZQzRkZ0pEd0x3aHo3NlNQVlZtNzJJRXFNU0F2ak8tcjNTUUxfSlUzZXVzVE1fbWc3VFdXNnhKLUtsV0JfTUlWN09UTXhqdndtdVVBNEowbEozTG1aYXd4OGU5LWdONTlXNU5ZSXN5S3l3UVBVcVBoeWNDV19pMG1TX0lJWE9JZGtwZEZiVXktcVlYVmYwNVlZRHZzN1Nka0ZiYXJCT21XalNDSw?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-01T08:00:00+00:00", "published_display": "01 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 62, "sentiment_summary": {"positive": 13, "negative": 18, "neutral": 31, "score": 44, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 16.1, "count": 28}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 6.6, "count": 12}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.45, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 1.1, "count": 2}], "positive_events": 13, "negative_events": 18}, "market_context": {"has_market_context": true, "latest_close": 10.28, "latest_week": "2026-07-10", "one_week_move": 10.8, "four_week_move": 17.7, "twelve_week_move": -23.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.872879, "market_dynamics_buy_signal": false, "relative_strength": -3.580325, "fair_value_gap": 63.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.8419, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+10.8% over one week, +17.7% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "Stock Titan", "count": 9}, {"label": "TradingView", "count": 7}, {"label": "simplywall.st", "count": 5}, {"label": "Stocktwits", "count": 4}, {"label": "Pluang", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "GlobeNewswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 14}, {"label": "Regulatory and legal", "count": 12}, {"label": "Deals and strategy", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Capital return", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "44/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+10.8% over one week, +17.7% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return"}], "updated_at": "2026-07-16T05:53:16.395946+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}